Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting

Rhea-AI Summary

Kintara Therapeutics (Nasdaq: KTRA) announced it will present data at the 2022 AACR Annual Meeting in New Orleans from April 8-13, 2022. The presentation focuses on VAL-083, a first-in-class chemotherapeutic for Glioblastoma Multiforme (GBM), highlighting its mechanism of crossing the blood-brain barrier. Kintara is also advancing REM-001, a therapy for Cutaneous Metastatic Breast Cancer (CMBC), which has shown an 80% complete response rate in prior trials. The company is committed to developing effective cancer therapies for patients with unmet needs.

Positive

• Kintara will present promising data on VAL-083 for GBM at AACR 2022.
• VAL-083 demonstrates clinical activity across multiple solid tumors.
• REM-001 shows an 80% complete response rate in CMBC trials.

Negative

• Forward-looking statements indicate potential risks related to clinical trial timelines and funding availability.

SAN DIEGO, March 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that it will be presenting data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.  The AACR 2022 Annual Meeting will be held from April 8 through April 13, 2022 in New Orleans.

Data Presentation:

Track 24:  Experimental and Molecular Therapeutics

Session PO.ET02.01 - Mechanisms of Drug Action 1

1843 / 15 - Dianhydrogalactitol (VAL-083) for the Treatment of Glioblastoma Multiforme (GBM): Impact of Glucose Transporters for Crossing the Blood Brain Barrier (BBB)

(Presentation Time: Monday, April 11, 2022 - 1:30 to 5:00 pm CT)

About Kintara
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs.  The two programs are VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).

VAL-083 is a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the GBM AGILE study to support the development and commercialization of VAL-083 in GBM.

Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and LinkedIn.

SAFE HARBOR STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study.  Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.  The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.  These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2021, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

CONTACTS

Investors:
CORE IR
516-222-2560
ir@coreir.com

Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-data-presentation-at-the-2022-american-association-for-cancer-research-annual-meeting-301502520.html

SOURCE Kintara Therapeutics

FAQ

What is Kintara Therapeutics presenting at the AACR Annual Meeting 2022?

Kintara is presenting data on VAL-083 for Glioblastoma Multiforme, focusing on its ability to cross the blood-brain barrier.

When is Kintara's presentation scheduled at the AACR 2022?

The presentation is scheduled for April 11, 2022, from 1:30 to 5:00 pm CT.

What are the key therapies being developed by Kintara Therapeutics?

Kintara is developing VAL-083 for GBM and REM-001 for Cutaneous Metastatic Breast Cancer.

What success has Kintara Therapeutics seen with REM-001?

REM-001 has shown an 80% complete response rate in patients with Cutaneous Metastatic Breast Cancer.